The Role of Personal Opinions and Experiences in Compliance with Mass Drug Administration for Lymphatic Filariasis Elimination in Kenya

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Njomo, Doris W ^a,c   Amuyunzu Nyamongo, Mary ^b   Magambo, Japheth K ^c   Njenga, Sammy M ^a  

^a KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^b African Institute for Health and Development   (Kenya)

^c JOMO KENYATTA UNIVERSITY OF AGRICULTURE AND TECHNOLOGY   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERSE DRUG REACTION; ARTICLE; ATTITUDE TO HEALTH; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG USE; FEMALE; HEALTH CARE DELIVERY; HEALTH EDUCATION; HEALTH PROGRAM; HUMAN; INTERVIEW; KENYA; LYMPHATIC FILARIASIS; MAJOR CLINICAL STUDY; MALE; MASS DRUG ADMINISTRATION; PATIENT COMPLIANCE; PUBLIC HEALTH; PUBLIC OPINION; QUESTIONNAIRE; RETROSPECTIVE STUDY; SOCIAL SUPPORT; SUBSTANCE ABUSE;

ADOLESCENT; ADULT; ALCOHOLISM; ELEPHANTIASIS, FILARIAL; FAMILY CHARACTERISTICS; FEMALE; FILARICIDES; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; KENYA; MALE; MIDDLE AGED; PATIENT COMPLIANCE; SOCIAL SUPPORT; SUBSTANCE-RELATED DISORDERS; YOUNG ADULT;

EID: 84869805936     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0048395     Document Type: Article

References (33)

1. World Health Organization (1995b) World Health Report, Geneva. pp118.
2. World Health Organization (2004) Lymphatic filariasis: progress of disability prevention activities. Wkly Epidemiol Rec 79: 417-24.
3. Bockarie M, Molyneux D, (2009) The end of lymphatic filariasis? Tropical Diseases. British Medical Journal 338: b 1686.
4. Centres for Disease Control and Prevention (1993) Recommendations of the International Task Force for Disease Eradication. MMWR Recomm. Rep 42: 1-38.
5. Stolk WA, Swaminathan S, van Oortmarssen GJ, Das PK, Habbema JD, (2003) Prospects for elimination of bancroftian filariasis by mass drug treatment in Pondicherry, India: a simulation study. J Infect Dis 188: 1371-1381.
6. Plaisier AP, Stolk WA, van Oortmarssen GJ, Habbema JD, (2000) Effectiveness of annual ivermectin treatment for Wuchereria bancrofti infection. Parasitol Today 16: 298-302.
7. Damer TE (2008) Attacking Faulty Reasoning: A Practical Guide to Fallacy-free Arguments. Cengage Learning Wardsworth Publishing pp. 14-15.
8. Christensen SM, Turner DR, (1993) Folk psychology and the philosophy of mind. Routledge.
9. Kenya Population and housing census highlights (2009) Kenya National Bureau of Statistics.pp.1-8.
10. Mukoko DA, Pedersen EM, Masese NN, Estambale BB, Ouma H, (2004) Bancroftian filariasis in 12 villages in Kwale district, Coast province, Kenya- variation in clinical and parasitological patterns. Ann Trop Med Parasitol 98: 801-815.
11. Njenga SM, Muita M, Kirigi G, Mbugua J, Mitsui Y, et al. (2000) Bancroftian filariasis in Kwale district, Kenya. East Afr Med J 77: 245-249.
12. Njenga SM, Wamae CN, Njomo DW, Mwandawiro CS, Molyneux DH, (2008) Impact of two rounds of mass treatment with diethylcarbamazine plus albendazole on Wuchereria bancrofti infection and the sensitivity of immunochromatographic test in Malindi, Kenya. Trans R Soc Trop Med Hyg 102: 1017-1024.
13. Brown CA, Sohani SB, Khan K, Lilford R, Mukhwana W, (2008) Antenatal care and perinatal outcomes in Kwale district, Kenya. BMC Pregnancy and Childbirth 8: 2.
14. Carter A, (2010) Factors that contribute to the low uptake of skilled care during delivery in Malindi, Kenya. SIT Study Abroad.
15. Khan ME, Anker M, Patel BC, Barge S, Sadhwani H, et al. (1991) The use of focus groups in social and behavioral research: some methodological issues. World Health Statistics Quarterly 44: 145-149.
16. Babu BV, Kar SK, (2004) Coverage, compliance and some operational issues of mass drug administration during the programme to eliminate lymphatic filariasis in Orissa India. Trop Med Int Health 9: 702-709.
17. Njomo DW, Amuyunzu-Nyamongo M, Magambo JK, Ngure PK, Njenga SM, (2012) Factors associated with the motivation of community drug distributors in the Lymphatic Filariasis Elimination Programme in Kenya. South Afr J Epidemiol Infect 2: 66-70.
18. Wanji S, Tendongfor N, Nji T, Esum M, Che JN, et al. (2009) Community-directed delivery of doxycycline for the treatment of onchocerciasis in areas of co-endemicity with loiasis in Cameroon. Parasites and Vectors 2: 2-39.
19. Katabarwa N, Mutabazi D, (1998) The selection and validation of indicators for monitoring progress towards self-sustainment in community-directed, ivermectin-treatment programmes for onchocerciasis control in Uganda. Ann Trop Med Parasitol 94: 343-352.
20. Mathieu E, Direny AN, Rochars MB, Streit TG, Adiss DG, et al. (2006) Participation in three consecutive mass drug administrations in Leogane, Haiti. Trop Med Int Health 11: 862-868.
21. Weerasooriya MV, Yahathugoda CT, Wickramasinghe D, Gunawardena KN, Dharmadasa RA, et al. (2007) Social mobilization, drug coverage and compliance and adverse reactions in a Mass Drug Administration (MDA) Programme for the Elimination of Lymphatic Filariasis in Sri Lanka. Filaria J 6: 6-11.
22. Lakwo TL, Gasarasi DB, (2006) Non-adherence to community-directed treatment with ivermectin for onchocerciasis control in Rungwe district, southwest Tanzania. East Afr Med J 83 (6) (): 326-332.
23. Mathieu E, Lammie PJ, Raddy J, Beach MJ, Streit T, et al. (2004) Factors associated with participation in a campaign of mass treatment against lymphatic filariasis, in Leogane, Haiti. Ann Trop Med Parasitol 98: 703-714.
24. Ramaiah KD, Das PK, Appavoo NC, Ramu K, Augustin DJ, et al. (2000) A programme to eliminate lymphatic filariasis in Tamil Nadu State, India: Compliance with annual single dose mass treatment and some related operational aspects. Trop Med Int Health 5: 842-847.
25. McLaughlin SI, Radday J, Micheal MC, Adiss DG, Beach MJ, (2003) Frequency, severity and costs of adverse reactions following mass treatment for lymphatic filariasis using diethylcarbamazine and albendazole in Leogane, Haiti. Am J Trop Med Hyg 68: 568-573.
26. Babu BV, Satyanarayana K, (2003) Factors responsible for coverage and compliance in mass drug administration during the programme to eliminate lymphatic filariasis in the East Godavari district, South India. Tropical Doctor 33: 79-82.
27. Evans DB, Geland H, Vlassof C, (1993) Social and economic factors and the control of lymphatic filariasis: a review. Acta Trop 53: 1-26.
28. Kyelem D, (2007) Epidemiology and Control of Lymphatic Filariasis in Burkina Faso. Ph.D. Thesis, Liverpool School of Tropical Medicine. The University of Liverpool pp. 252-254.
29. Njomo DW, Amuyunzu-Nyamongo M, Mukoko DA, Magambo JK, Njenga SM, (2012) Social Mobilization and Compliance with Mass Treatment for Lymphatic Filariasis Elimination in Kenya. Afr J Health Sci 20: 42-49.
30. Mohammed K, Molyneux D, Albonico M, Rio F, (2006) Progress towards eliminating lymphatic filariasis in Zanzibar: a model programme. Trends Parasitol 22: 340-344.
31. Amarillo ML, Belizario VY Jr, Sadiang-abay JT, Sison SA, Dayag AM, (2008) Factors associated with acceptance of mass drug administration for the elimination of lymphatic filariasis in Agusan del Sur, Philippines. Parasites and Vectors 1: 1-14.
32. Stroebe W (2000) Moderators of the stress-health relationship: Stroebe W. Social Psychology and Health. Philadelphia, PA: Open University Press 236-273.
33. Yirga D, Deribe K, Woldemicheal K, Wendafrash M, Kassahun W, (2010) Factors associated with compliance with community directed treatment with ivermectin for onchocerciasis control in Southwestern Ethiopia. Parasites and Vectors 3: 3-48.